The Effect of Concomitant Administration of Erythromycin and Diltiazem on CYP3A Activity in Healthy Volunteers

NCT ID: NCT00318201

Last Updated: 2012-04-06

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE4
• Total Enrollment: 7 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2006-04-30
• Study Completion Date: 2007-12-31

Brief Summary

We, the researchers at the Indiana University School of Medicine, are doing this study to better understand how the effects of certain medications are altered when taken simultaneously, or in combination with each other. We will also look at how each volunteer's genes (DNA) may affect the way these medications are metabolized.

Hypothesis:

We will test the hypothesis that the extent of drug-drug interaction caused by the combination of erythromycin and diltiazem is not predictable from the extent of interaction produced by each inhibitor alone. Specifically we will test the hypothesis that the combination of erythromycin and diltiazem will cause a greater decrease in midazolam intravenous and oral clearance than the sum of the decreases caused by each inhibitor alone.

Detailed Description

Many drugs such as diltiazem are metabolized by CYP3A4, the cytochrome P450 enzyme responsible for the metabolism of erythromycin and when given together, the possibility exists that one drug inhibits the metabolism of the other leading to an increase in plasma concentration. The magnitude of this interaction is not known. It is therefore important to define this effect because diltiazem is a drug that is used commonly to treat hypertension, angina and atrial fibrillation and these patients may be given erythromycin for the treatment of intercurrent bacterial infections.

Conditions

Healthy

Study Design

• Allocation Method: NON_RANDOMIZED
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

1

Altered efficacy for drug to drug interaction of diltiazam with erythromycin

Group Type: EXPERIMENTAL

Erythromycin

Intervention Type: DRUG

Diltiazem

Intervention Type: DRUG

Interventions

Erythromycin

Intervention Type: DRUG

Diltiazem

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

Approximately 45 healthy volunteers may be recruited to participate in the study, with a goal of 15 healthy volunteers (7 or 8 males) completing the entire four phases. All potential subjects:

1. Must be a non-smoker

2. Between 18 to 50 years of age

3. Have a body mass index of 30 or less

4. Must be willing to undergo a screening physical examination and proven to be free from metabolic, cardiac, pulmonary, renal or hepatic dysfunction as determined by the screening physical, medical history, 12-lead electrocardiography, and laboratory values which include: a CMP (complete metabolic profile), a CBC/diff/plt (complete blood count with differential and platelet count), serum pregnancy test (if applicable), and UA (urinalysis). Also, given the uncertain effects of these drugs on the fetus and the fact that hormonal contraceptives are prohibited, the female subjects should be on two other forms of birth control (e.g. condom, contraceptive foam).

Exclusion Criteria

Potential volunteers will be excluded:

1. If they have allergies or are hypersensitive to any of the study medications:

A. Midazolam (Versed) or related benzodiazepines drugs such as diazepam (Valium) or alprazolam (Xanax).

B. Diltiazem (Cardizem, Dilacor) or related calcium channel blockers such as verapamil (Calan, Isoptin).

C. Erythromycin (Erythrocin, E-mycin, Ery-tab) or related antibiotics such as clarithromycin (Biaxin) or have experienced abdominal pain when taking erythromycin or other related medications.

2. If they are taking any prescription medication on a regular basis including contraceptives such as oral birth control pills, transdermal patches or injections (Depo-Provera).

3. If they are taking over-the-counter medications, any herbal or dietary supplement (including Benadryl, Sudafed, St. John's wort, herbal teas, vitamins and garlic supplements) that cannot be stopped for the study duration. Use of over-the-counter drugs for the treatment of minor, short-lived (2 to 3 days) symptoms may be allowable (such as Tylenol) but must first be approved by a study investigator.

4. If they have donated blood within the past two months, or are anemic (have a hemoglobin level less than 12.5 mg/dl).

5. If they weigh less than 52 kg, or have a BMI (Body Mass Index) greater than 32.

6. If they have a screening or baseline EKG reading that is abnormal or could place them at higher risk as decided by the study doctors (baseline corrected QT interval in the EKG of 450 msec or greater or a baseline PR interval in the EKG of 210 msec or greater).

7. If they have a history of bradycardia or consistently have a heart rate less than 55 beats per minutes.

8. If they have any history of heart disease or have a family medical history of sudden death (heart stopping suddenly without warning).

9. If they have a history of psychiatric problems that may be exacerbated by participation in this study, or if the subject can not state a good understanding of this study's risks and requirements.

10. If they have a positive serum pregnancy test during the screening process or have a positive urine pregnancy test (UPT) which will be obtained just prior to each of the four study phases.

11. If they are currently breastfeeding.

12. If they have participated in any other study in which they have taken a research medication within the past three months.

13. If they have a history of alcohol or drug abuse, or have used tobacco or marijuana within the past three months.

14. If they are unwilling or unable to refrain from using drugs, alcohol, or any food listed on the exclusion list below during this study.

15. If they are an employee or student under the supervision of any study investigator.

16. If they are unwilling or unable to follow the study rules.

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 50 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: Yes

Sponsors

Indiana University School of Medicine

OTHER

Sponsor Role: lead

Responsible Party

Indiana University

Principal Investigators

Stephen D Hall, PhD

Role: PRINCIPAL_INVESTIGATOR

Indiana University

Locations

Indiana University Medical Center / GCRC

Indianapolis, Indiana, United States

Countries

United States

Other Identifiers

R01GM067308/NIGMS

Identifier Type: -

Identifier Source: secondary_id

MO1RR000750/GCRC #1267

Identifier Type: -

Identifier Source: secondary_id

R01GM067308

Identifier Type: NIH

Identifier Source: secondary_id

View Link

# 0412-09

Identifier Type: -

Identifier Source: org_study_id